Physician profile
Paige Burrell
NPI 1982378881
$4,382.41
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $317 · 2022: $1,418 · 2023: $1,627 · 2024: $1,020.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,647.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,646.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $514.91 | 2021-2024 | |
| Novo Nordisk INC | $461.10 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $390.52 | 2022-2024 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $372.20 | 2021-2024 | Jardiance, Ofev, Spiriva Respimat |
| Lilly USA, LLC | $338.67 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $327.55 | 2022-2024 | Shingrix, Trelegy Ellipta, Arexvy |
| Myriad Women'S Health, INC. | $314.37 | 2023 | Myrisk |
| Pfizer INC. | $310.91 | 2021-2024 | |
| Daiichi Sankyo INC. | $187.64 | 2021-2024 | Injectafer |
| Otsuka America Pharmaceutical, INC. | $130.97 | 2023-2024 | Rexulti |
| Bayer Healthcare Pharmaceuticals INC. | $106.18 | 2022-2024 | |
| Amgen INC. | $105.33 | 2022-2024 | Repatha, Otezla |
| Merck Sharp & Dohme LLC | $97.20 | 2021-2024 | Gardasil 9, Pneumovax 23, Vaxneuvance |
| Exact Sciences Corporation | $78.38 | 2023-2024 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $64.79 | 2021-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $64.26 | 2024 | Xifaxan |
| E.R. Squibb & Sons, L.L.C. | $58.74 | 2022-2023 | Eliquis |
| Biohaven Pharmaceutical Holding Company LTD. | $52.57 | 2022 | |
| Amarin Pharma, INC. | $46.12 | 2022 | |
| Janssen Pharmaceuticals, INC | $41.84 | 2023 | Spravato |
| Biohaven Pharmaceuticals, INC. | $38.01 | 2021 | |
| Edwards Lifesciences Corporation | $37.20 | 2023-2024 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Amneal Pharmaceuticals LLC | $32.60 | 2021 | |
| Lundbeck LLC | $27.70 | 2023 | Rexulti |
| Almatica Pharma LLC | $24.94 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $24.44 | 2022 | |
| Axsome Therapeutics, INC. | $22.45 | 2022 | |
| Novartis Pharmaceuticals Corporation | $18.39 | 2023 | Entresto, Leqvio |
| Gilead Sciences, INC. | $18.27 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $17.53 | 2021 | |
| Corcept Therapeutics | $16.25 | 2024 | Korlym |
| Ibsa Pharma INC. | $15.38 | 2024 | Tirosint, Licart |
| Sanofi-Aventis U.S. LLC | $13.78 | 2023 | |
| Clarus Therapeutics INC. | $11.22 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paige Burrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.